Cigna earnings beat by $0.04, revenue topped estimates
UroGen Pharma Ltd. (NASDAQ:URGN), a biopharmaceutical company with a market capitalization of approximately $598 million, disclosed that its board of directors approved one-time special bonuses for three executive officers on June 30, 2025. According to a statement in a press release and an SEC filing, the bonuses were awarded to Elizabeth Barrett, President and Chief Executive Officer, Chris Degnan, Chief Financial Officer, and Jason Smith, General Counsel and Chief Compliance Officer.
Elizabeth Barrett received a bonus of $645,000. Chris Degnan and Jason Smith were each awarded bonuses of $100,000. The company stated these awards recognized the executives’ leadership and contributions leading up to and including the U.S. Food and Drug Administration’s approval of ZUSDURI for the treatment of recurrent low-grade intermediate risk non-muscle invasive bladder cancer.
UroGen Pharma is incorporated in Israel and its ordinary shares are listed on The Nasdaq Stock Market LLC under the symbol URGN.
This information is based on a press release statement and a Form 8-K filing with the Securities and Exchange Commission.
In other recent news, UroGen Pharma has received FDA approval for its bladder cancer treatment, ZUSDURI, designed for adults with recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer. This approval follows the Phase 3 ENVISION trial results, showing a 78% complete response rate at three months, with 79% of patients maintaining their response after a year. The treatment is expected to be available in the U.S. starting July 1, 2025. Additionally, H.C. Wainwright upgraded UroGen Pharma’s stock rating to buy, setting a price target of $50.00, while Oppenheimer raised its target to $31.00, maintaining an Outperform rating. Scotiabank (TSX:BNS) also increased its price target to $47.00, citing the drug’s positive benefit/risk profile. Guggenheim raised its target to $30.00, projecting ZUSDURI could capture 15% of the market, potentially generating $800 million in U.S. sales at peak in 2030. Analysts from these firms highlight the drug’s market potential, with projections reaching up to $1 billion in sales. UroGen Pharma’s commercial strategy includes completing the ongoing ENVISION trial and providing annual updates on the treatment’s duration of response.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.